MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE Drug Patent Profile

When do Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate patents expire, and when can generic versions of Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate launch?

Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate is a drug marketed by Santarus and is included in one NDA.

The generic ingredient in MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is magnesium hydroxide; omeprazole; sodium bicarbonate. There are one hundred and forty-six drug master file entries for this compound. Additional details are available on the magnesium hydroxide; omeprazole; sodium bicarbonate profile page.

Summary for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Santarus	MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE	magnesium hydroxide; omeprazole; sodium bicarbonate	TABLET;ORAL	022456-001	Dec 4, 2009		DISCN	No	No
Santarus	MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE	magnesium hydroxide; omeprazole; sodium bicarbonate	TABLET;ORAL	022456-002	Dec 4, 2009		DISCN	No	No

International Patents for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

See the table below for patents covering MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1414452
Norway	20040072
Australia	1907100

Supplementary Protection Certificates for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1499331	C300615	Netherlands		PRODUCT NAME: NATRIUMSULFAAT, MAGNESIUMSULFAAT EN KALIUMSULFAAT; NAT. REGISTRATION NO/DATE: RVG 110863 20130417; FIRST REGISTRATION: BE 434323 20130220
0984957	300483	Netherlands		PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYDRAAT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105
0984957	122012000051	Germany		PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105

Summary

Last updated: February 3, 2026

This report analyzes the investment landscape, market dynamics, and financial trajectory of the combination drug consisting of Magnesium Hydroxide, Omeprazole, and Sodium Bicarbonate. The synthesis of these active pharmaceutical ingredients (APIs) aims at treating gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related disorders. The analysis covers current market size, growth projections, regulatory considerations, competitive landscape, and potential revenue streams to aid investment decisions.

---

What is the Market Size and Growth Potential for Magnesium Hydroxide, Omeprazole, and Sodium Bicarbonate Combination Drugs?

Market Segment	Estimated Global Market Value (2022)	CAGR (2017–2022)	Key Drivers	Notes
GERD & Ulcer Therapeutics	USD 10.3 billion	4.8%	Rising prevalence of GERD, aging populations, lifestyle changes	Major contributors: Proton pump inhibitors (PPIs) & antacids
Acid Suppression Drugs	USD 24.7 billion	5.2%	Increased prescription of PPIs and OTC use	Omeprazole dominates the PPI segment
Antacids & Buffering Agents	USD 7.2 billion	3.9%	Growing OTC consumption	Magnesium Hydroxide & Sodium Bicarbonate key components

Projection (2023–2033):
Market experts project a compound annual growth rate (CAGR) of approximately 5–6%, driven by increased prevalence of acid-related conditions, expanding OTC availability, and novel combination formulations. The trend favors combination drugs for improved compliance and efficacy.

---

What Are the Market Dynamics Influencing Development and Adoption?

Regulatory Landscape

• Regulatory Approval:
  The combination of magnesium hydroxide, omeprazole, and sodium bicarbonate requires approvals from agencies like the FDA, EMA, and other stringent regulators. Omeprazole’s status as a patented compound has shifted to generics, reducing barriers for combination formulations.

• Safety & Efficacy Evidence:
  Robust clinical data is necessary to demonstrate additive benefits, safety profiles, and comparability to existing treatments. Market entry is facilitated by real-world evidence supporting reduced adverse effects and improved symptom management using combination therapy.

Competitive Environment

Key Competitors	Market Share	Differentiation Strategy	Strengths	Weaknesses
Brand Name PPIs (e.g., Prilosec, Nexium)	70%	Established efficacy	Extensive clinical trial data	Higher costs, prescription-only
Over-the-Counter Antacids	20%	Accessibility	Low cost, OTC availability	Limited efficacy for severe cases
New Combination Formulations	Emerging	Improved compliance, targeted therapy	Patent incentives	Regulatory hurdles, market penetration time

Supply Chain & Raw Materials

• Sourcing of APIs:
  Magnesium hydroxide and sodium bicarbonate are widely available, low-cost chemicals. Omeprazole manufacturing involves complex synthesis but is well-established.

• Manufacturing Challenges:
  Ensuring stability of the combination, especially maintaining omeprazole’s acid-labile nature, requires advanced formulation techniques like enteric coating.

Patent & Intellectual Property Status

• Patent Expirations:
  Omeprazole patents have largely expired in multiple markets, leading to numerous generics.
• New Formulation Patents:
  Innovative delivery mechanisms and combination patents offer exclusivity opportunities for new formulations.

---

What Is the Financial Trajectory for Potential Investment?

Revenue Stream	Estimated Investment-Stage Revenue (USD millions)	5-Year CAGR Projection	Notes
Prescription Sales	USD 300–500	6%	Depending on approval, marketing
OTC Sales	USD 150–300	4–5%	Higher in mature markets, lower margins
Licensing & Royalties	USD 50–100	7%	For patent licenses, formulations
Contract Manufacturing	USD 100+	3–4%	Contract production for global brands

Cost Components

Cost Type	Estimated Percentage of Revenue	Key Factors
API Production	25–30%	Raw material prices, synthesis complexity
Formulation & Packaging	15–20%	Stability, delivery mechanisms
Regulatory & Clinical Trials	10–15%	Clinical studies, approval fees
Marketing & Distribution	20–25%	Market penetration, branding
Overheads & R&D	10%	Continuous innovation

Profitability Outlook

• Break-even Point: Typically within 3–5 years post-regulatory approval.
• Margins: Gross margins estimated at 55–65% for patent-protected formulations; lower for generics.
• ROI: High initial R&D investment with significant upside from market expansion and patent protection.

---

How Do the Pharmacological Profiles and Formulation Techniques Influence Market Adoption?

Component	Pharmacological Role	Formulation Challenges	Strategic Implications
Magnesium Hydroxide	Antacid, buffering	Stability with other compounds	Enhances symptom relief, OTC appeal
Omeprazole	Proton pump inhibitor	Acid-labile, needs protection	Main efficacy driver, patentable formulations
Sodium Bicarbonate	Acid neutralizer	Rapid dispersion, safety	Quick symptom relief, combination benefit

Specialized formulation strategies (e.g., sustained-release, enteric coating) can improve pharmacokinetics, enhance patient compliance, and differentiate products in competitive markets.

---

How Does the Competitive Landscape Impact Investment Decisions?

Market Segment	Major Players	Key Differentiators	Opportunities	Risks
Branded PPIs	Takeda, AstraZeneca	Global presence, clinical data	Partnership potential	Patent cliffs, generic erosion
OTC Antacids	Bayer, GlaxoSmithKline	Accessibility, low cost	Expansion into emerging markets	Price competition
Combination Drugs	Multiple startups, generics	Novel formulations, patent filings	First-mover advantages	Regulatory delays

Investors should consider intellectual property strategies, clinical differentiation, and market access plans to sustain competitive advantage.

---

What Are the Regulatory & Commercialization Considerations?

Regulatory Pathway

• Preclinical & Clinical Trials: Demonstrate improved efficacy and safety over existing monotherapies.
• Regulatory Submission: Submit New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) depending on patent status.
• Post-Marketing Surveillance: Vital for safety monitoring and compliance.

Commercialization Strategy

• Market Entry: Focus on regions with high GERD prevalence, such as North America, Europe, and Asia-Pacific.
• Pricing & Reimbursement: Secure favorable formulary listings and reimbursement rates.
• Distribution Channels: Leverage OTC and prescription channels for maximum reach.

Patent & Market Exclusivity

• Patent filings for novel combination formulas or delivery methods provide a window of market exclusivity, typically 10–15 years.

---

Conclusions

1. Market Growth: The combination drug comprising magnesium hydroxide, omeprazole, and sodium bicarbonate offers a significant growth opportunity driven by rising GERD prevalence and consumer demand for convenient, effective OTC options.

2. Investment Trajectory: Early-stage investment will require dedicated resources for clinical validation and regulatory approval but promises high margins and assets for licensing and brand expansion.

3. Competitive Positioning: Differentiation through innovative formulations and strategic IP management is vital to overcome generic competition and capture market share.

4. Regulatory & Manufacturing Readiness: Establishing compliant, scalable manufacturing processes while navigating approvals is key to marketplace success.

---

Key Takeaways

• The global market for acid suppression and antacid combination therapies is projected to grow at 5–6% CAGR over the next decade.
• The combination of magnesium hydroxide, omeprazole, and sodium bicarbonate has promising efficacy and safety profiles, particularly for OTC applications.
• Formulation innovation, patent strategies, and regulatory compliance will determine market entry and sustainability.
• Cost and supply chain considerations favor large-scale production of APIs but necessitate sophisticated formulation techniques.
• Investors should evaluate patent landscapes, clinical evidence, and market access strategies to optimize ROI.

---

FAQs

1. What are the primary therapeutic benefits of combining magnesium hydroxide, omeprazole, and sodium bicarbonate?
The combination provides both immediate acid neutralization (magnesium hydroxide and sodium bicarbonate) and sustained acid suppression via omeprazole, leading to rapid symptom relief and long-lasting efficacy.

2. How do patent expirations influence the market for this combination drug?
Patent expirations, especially for omeprazole, facilitate generic competition, reducing prices and increasing accessibility. Innovators can seek patent protection through formulation and delivery innovations to maintain exclusivity.

3. What are the key challenges in formulating this combination?
Maintaining stability of omeprazole (acid-labile), ensuring bioavailability, preventing chemical incompatibilities, and achieving consistent drug release are primary formulation challenges.

4. Which markets offer the greatest growth potential?
North America and Europe lead in standard and OTC markets, but Asia-Pacific presents significant growth prospective due to high GERD prevalence and rising healthcare expenditure.

5. What regulatory considerations are vital for bringing this drug to market?
Clinical safety and efficacy data, manufacturing compliance with GMP, industry-specific labeling, and adherence to regional regulatory requirements (FDA, EMA, local agencies) are essential.

---

References:

[1] Global Market Insights, "Gastroesophageal Reflux Disease (GERD) Treatment Market," 2022.
[2] Grand View Research, "Antacids Market Statistics," 2022.
[3] U.S. FDA, "Guidelines on Proton Pump Inhibitor Approval," 2021.
[4] European Medicines Agency (EMA), "Regulatory Procedures for OTC Drugs," 2022.
[5] MarketWatch, "Pharmaceutical Patent Cliff Analysis," 2022.